GSK Announces Intention To Sell 270M Shares In Haleon
Portfolio Pulse from Benzinga Newsdesk
GSK plc has announced its intention to sell 270 million ordinary shares in Haleon, equivalent to approximately 2.9% of Haleon's issued share capital. The disposal will be conducted through a placing of ordinary shares in Haleon to institutional investors. The offer price of Haleon share sale will be determined by means of an accelerated bookbuild offering process which is to start immediately.
October 05, 2023 | 3:52 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
GSK's decision to sell a significant portion of its shares in Haleon could potentially impact its own stock price, depending on the outcome of the sale.
The sale of a significant portion of GSK's shares in Haleon could potentially impact GSK's own stock price. The impact will depend on the outcome of the sale, including the final sale price and the market's reaction to the sale.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
The sale of 270 million shares in Haleon by GSK could potentially impact Haleon's stock price, depending on the outcome of the sale.
The sale of a significant portion of shares in Haleon could potentially impact Haleon's own stock price. The impact will depend on the outcome of the sale, including the final sale price and the market's reaction to the sale.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100